Skip to main content
. 2023 Jan 31;20(3):2565. doi: 10.3390/ijerph20032565

Figure 2.

Figure 2

Proportion of cancer patients receiving various targeted therapies in combination with Helixor® VA therapy (COMB group, n = 82). CDK 4/6 inhibitors (CDKi), immune checkpoint inhibitors (ICI), monoclonal antibodies (mAB), PARP-inhibitors (PARPi), TKI-inhibitors (TKI).